MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

25.77 -0.54

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25.77

Max

26.12

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-5.8M

40M

Pardavimai

16M

200M

P/E

Sektoriaus vid.

8.503

36.442

Pelnas, tenkantis vienai akcijai

0.92

Pelno marža

19.839

Darbuotojai

268

EBITDA

3M

59M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+72.05% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-10-28

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-514M

1.5B

Ankstesnė atidarymo kaina

26.31

Ankstesnė uždarymo kaina

25.77

Naujienos nuotaikos

By Acuity

67%

33%

321 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-19 20:00; UTC

Įsigijimai, susijungimai, perėmimai

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

2025-10-19 23:44; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

2025-10-19 23:37; UTC

Rinkos pokalbiai

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

2025-10-19 23:36; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

2025-10-19 23:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-19 23:09; UTC

Rinkos pokalbiai

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

2025-10-19 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

2025-10-19 22:30; UTC

Uždarbis

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

2025-10-19 22:18; UTC

Rinkos pokalbiai

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

2025-10-19 21:50; UTC

Rinkos pokalbiai

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

2025-10-19 21:15; UTC

Rinkos pokalbiai

Investors Need to Change Narrative Toward Scales -- Market Talk

2025-10-19 19:34; UTC

Įsigijimai, susijungimai, perėmimai

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

2025-10-19 19:34; UTC

Įsigijimai, susijungimai, perėmimai

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

2025-10-19 19:33; UTC

Įsigijimai, susijungimai, perėmimai

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

2025-10-19 19:32; UTC

Įsigijimai, susijungimai, perėmimai

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

2025-10-19 19:32; UTC

Įsigijimai, susijungimai, perėmimai

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

2025-10-19 19:31; UTC

Įsigijimai, susijungimai, perėmimai

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

2025-10-19 19:31; UTC

Įsigijimai, susijungimai, perėmimai

Infratil to Acquire Additional 4.92% Stake in Contact Energy

2025-10-19 16:29; UTC

Uždarbis

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

2025-10-19 11:14; UTC

Uždarbis

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

2025-10-19 11:14; UTC

Uždarbis

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

2025-10-19 11:14; UTC

Uždarbis

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

2025-10-18 13:30; UTC

Įsigijimai, susijungimai, perėmimai

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

2025-10-18 13:30; UTC

Įsigijimai, susijungimai, perėmimai

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

2025-10-18 13:30; UTC

Įsigijimai, susijungimai, perėmimai

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

2025-10-18 13:30; UTC

Įsigijimai, susijungimai, perėmimai

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

2025-10-18 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-10-17 23:25; UTC

Įsigijimai, susijungimai, perėmimai

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

2025-10-17 22:15; UTC

Rinkos pokalbiai

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

2025-10-17 21:15; UTC

Rinkos pokalbiai

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

72.05% į viršų

12 mėnesių prognozė

Vidutinis 44.56 USD  72.05%

Aukščiausias 62 USD

Žemiausias 31 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Very Strong Bearish Evidence

Rinkos nuotaikos

By Acuity

321 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat